Pediatric AsthmaNCT07582211
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
A study testing Bilevel positive airway pressure ventilation in people with Pediatric Asthma and Acute Asthma, run by Columbia University at 3 sites in United States.
Trial summary
The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach. Read more about this study
- Who is it for?
- Ages 5 to 17 years
- Conditions the study is for
- Pediatric Asthma, Acute Asthma, BiPAP
- What is being tested?
- Bilevel positive airway pressure ventilation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Dec 2026to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- 5 to 17 years of age (inclusive) presenting to the ED with an asthma exacerbation.
- Demonstrate moderate-severe asthma exacerbation at triage (i.e., receive an institutional asthma score equivalent to moderate-severe asthma exacerbation or a Pediatric Respiratory Assessment Measure (PRAM) score of 6 or above).
Who cannot join
- Prior participation in the study.
- Use of BPAP at any time within approximately 12 hours for this acute asthma exacerbation, including in prehospital, ED, or inpatient settings, prior to randomization.
- Receipt of continuous albuterol for over 150 minutes prior to being approached for consent.
- If a blood gas is obtained, PaCO2 greater than 60 mmHg on the most recent blood gas prior to being approached for consent.
- Note: Blood gas values are not required for eligibility confirmation.
- Anticipated immediate need (i.e., within approximately an hour after completion of first-line therapy) for invasive mechanical ventilation (e.g., endotracheal tube or laryngeal mask airway) or non-invasive mechanical ventilation (e.g., continuous positive airway pressure (CPAP) or BPAP), as determined by the treating physician.
Show all 23Show fewer
- Presence of a tracheostomy or a baseline requirement for noninvasive ventilation.
- Wheezing due to non-asthma causes (e.g., foreign body, tracheomalacia, vocal cord dysfunction, pulmonary edema, uncorrected congenital heart disease, cystic fibrosis, or anaphylaxis).
- Absolute or relative contraindication to BPAP, defined as any of the following:
- Facial trauma within the area where the face mask would be applied for BPAP (excluding minor abrasion or cuts on forehead or skull).
- Uncontrollable vomiting (i.e., > 3 episodes within approximately 1 hour prior to being approached for consent).
- Hypotension for age, defined as systolic blood pressure (SBP) less than 70 plus twice the patient's age in years (i.e., SBP < 70 + [2 x age in years]).
- Glasgow Coma Score of 8 or less.
- Known or clinical suspicion for air leak syndrome (e.g., pneumothorax, pneumomediastinum, pneumopericardium, or subcutaneous emphysema).
- Weight < 20 kg.
- Presence of an intra-abdominal mass compressing the stomach (e.g., due to tumor or large volume ascites) through EMR or medical history.
- Known or suspected pregnancy by history or if pregnancy test completed by clinical team.
- Any medical condition that, in the opinion of a site investigator, could 1) lead to difficulty complying with protocol procedures, 2) interfere with the safe completion of the study, or 3) affect the validity of the endpoint assessments.
- PRAM score less than 7 or greater than 10 based on concurrent clinical assessment by a healthcare provider after completion of standard first-line therapies, which is defined as receiving all of the following prior to ED arrival or during the ED encounter for this acute asthma exacerbation:
- Albuterol with or without ipratropium bromide, either at least 3 albuterol doses via inhalation method (e.g., metered-dose inhaler (MDI) or nebulized) or at least one hour of continuous albuterol (i.e., continuous nebulized albuterol or three consecutive intermittent nebulized albuterol treatments as bridging therapy).
- Corticosteroids (e.g., Prednisolone, Prednisone, Dexamethasone/Decadron, or Methylprednisolone) via enteral, intravenous, or intramuscular methods.
- Note: Oxygen is not a required first-line therapy.
- Do not require continuous albuterol or a second round of albuterol treatments (e.g., three back-to-back treatments or one hour of burst albuterol treatment) following completion of standard first-line therapies.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites
Nationwide Children's Hospital
Columbus, Ohio, 43205
Adjoa Andoh, MD, 614-355-3713, adjoa.andoh@nationwidechildrens.org
Columbia University Irving Medical Center
New York, New York, 10032
Maria Kwok, MD, MPH, 917-375-2647, myk2102@cumc.columbia.edu
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Joe Zorc, MD, MSCE, 215-590-5237, zorc@chop.edu
About this study
Official title: Bilevel Positive Airway Pressure (BPAP) for Severe Asthma Exacerbations: A Randomized Controlled Trial
The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach.
The main questions it aims to answer are:
Read more
- Can eligible patients be successfully enrolled and complete study procedures across multiple sites?
- What safety events occur with early BPAP use in this population?
- How do clinical outcomes (such as symptom improvement and need for intensive care) compare between early BPAP and standard care?
Researchers will compare early initiation of BPAP plus standard asthma therapy to standard asthma therapy alone to determine whether early BPAP is a feasible and potentially beneficial treatment strategy.
Participants will 1) receive standard asthma therapy with or without early BPAP in the ED, 2) be monitored closely during the ED visit and hospitalization, and 3) have clinical data collected from routine care, including asthma severity scores, treatments, and outcomes.
The study will enroll approximately 36 participants (about 12 per site) across three sites over one year to inform a future multicenter randomized controlled trial.
Read the detailed description
Severe asthma exacerbations are a common reason for pediatric emergency department (ED) visits, hospital admissions, and pediatric intensive care unit (PICU) use. Although first-line therapies such as inhaled beta-agonists, anticholinergics, and systemic corticosteroids are well established, the optimal second-line treatment for children who remain in moderate to severe respiratory distress is unclear.
Bilevel positive airway pressure (BPAP) is a form of non-invasive positive pressure ventilation that may improve airway patency, reduce work of breathing, improve ventilation-perfusion matching, and enhance delivery of inhaled bronchodilator therapy. Prior pediatric studies suggest potential physiologic and clinical benefit, but available randomized trials have been small and have generally evaluated BPAP after PICU admission rather than early in the ED course. Therefore, the feasibility, safety, and potential clinical impact of early ED initiation of BPAP remain uncertain.
This multicenter, randomized, unblinded feasibility trial will enroll approximately 36 children across three sites. Participants will be children with severe asthma exacerbations who remain symptomatic after completion of standard first-line therapy and continue to require continuous albuterol. Patients will be randomized to receive either BPAP plus continuous albuterol or continuous albuterol alone during an approximately 2-hour intervention period. BPAP will be delivered using FDA-cleared devices, with mask interface and pressure settings managed according to routine clinical practice. After the intervention period, all further asthma treatment and respiratory support will be determined by the treating clinical team.
The primary purpose of this study is to assess feasibility of conducting a future definitive multicenter randomized trial. Feasibility domains include patient identification, consent and assent processes, timely randomization, BPAP initiation and adherence, completion of asthma severity assessments, and collection of clinical and safety data. Clinical outcomes, including asthma severity, duration of continuous albuterol, BPAP use, ED disposition, PICU and hospital admission, length of stay, and readmission, will be summarized descriptively. Safety monitoring will include adverse events potentially related to BPAP or continuous albuterol, including air leak syndrome, vomiting, aspiration, hypotension, skin breakdown, tachycardia, and tremor.
This feasibility trial is not powered to detect treatment efficacy. Results will be used to refine trial procedures, assess protocol adherence, estimate enrollment and data completion rates, and inform the design of a future multicenter randomized trial evaluating whether early ED initiation of BPAP reduces critical care resource use and improves outcomes in children with severe asthma exacerbations.
- Being tested
- Bilevel positive airway pressure ventilation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bilevel positive airway pressure ventilationDevice
This study involves non-invasive positive pressure ventilation (NIPPV) delivered as bilevel positive airway pressure (BPAP) in children aged 5-17 years presenting to the pediatric emergency department with severe asthma exacerbations. BPAP will be administered using FDA-cleared devices according to their intended use and standard clinical practice. Therapy will be delivered via an appropriately fitted nasal or face mask and managed by trained clinical staff. Ventilator settings will be adjusted at the discretion of the treating clinician, and continuous bronchodilator therapy may be delivered through the BPAP circuit per manufacturer recommendations or site practice.
| Study group | Role | What they receive |
|---|---|---|
| BPAP plus continuous albuterol | Experimental | Participants randomized to this arm will receive BPAP plus continuous albuterol administered via FDA-approved delivery systems according to routine clinical practice. BPAP will be delivered using an appropriately sized nasal or face mask and managed by trained respiratory therapists and/or nursing staff per standard care. Continuous albuterol will be administered through the BPAP circuit per manufacturer recommendations or site-specific practice. BPAP settings may be adjusted at the discretion of the treating clinician. Participants will remain on BPAP for approximately 2 hours or until continuous albuterol is discontinued, whichever occurs first. After the intervention period, continuation of BPAP will be at the treating clinical team's discretion. Receives: Device: Bilevel positive airway pressure ventilation |
| Continuous albuterol alone | No intervention | Participants randomized to this arm will receive continuous albuterol administered via FDA-approved delivery systems according to routine clinical practice. Non-invasive ventilation (including BPAP or CPAP) will not be initiated during the first approximately 2 hours after randomization unless clinically indicated; if initiated, the reason will be documented. All other aspects of care, including oxygen and adjunctive therapies, will be provided at the discretion of the treating clinical team per standard practice. After the intervention period, escalation of care, including initiation of BPAP or other respiratory support, will be determined by the treating clinician. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of eligible patients who consent
Proportion of approached, eligible patients who provide consent.
Measured: From screening through randomization, up to 2 hours
Proportion of participants who adhere to the BPAP protocol among all those assigned to the BPAP arm
Proportion of participants in the intervention arm who receive > 1 hour \& 45 minutes of BPAP during the planned 2-hour intervention period without unplanned interruption (> 15 consecutive minutes), unless weaned off continuous albuterol.
Measured: From randomization through end of 2-hour intervention
Secondary outcomes (12)
Potential efficacy outcome: Change in Pediatric Respiratory Assessment Measure (PRAM) score
Change in Pediatric Respiratory Assessment Measure (PRAM) score from the pre-intervention to post-intervention assessment. The PRAM score ranges from 0 to 12, with higher scores indicating greater acute asthma exacerbation severity. Scores are categorized as mild (0-3), moderate (4-7), and severe (8-12).
Measured: Pre-intervention to end of intervention, approximately 3 hours total
Potential efficacy outcome: Duration of continuous albuterol use
Duration of continuous albuterol therapy
Measured: From randomization through hospital discharge beyond the intervention period, up to 120 hours.
Potential efficacy outcome: Duration of BPAP use
Duration of BPAP use
Measured: From randomization through hospital discharge beyond the intervention period, up to 120 hours
Potential efficacy outcome: PICU admission
Proportion of participants requiring admissions to the pediatric intensive care unit during the index ED visit
Measured: Disposition determined 2 hours after completion of the intervention period
Potential efficacy outcome: Hospital admission
Proportion of participants requiring hospital admission during the index ED visit
Measured: Disposition determined 2 hours after completion of the intervention period
Potential efficacy outcome: PICU length of stay
Length of stay in the PICU (hours) among participants admitted to the PICU.
Measured: From PICU admission to PICU discharge, up to 120 hours
Potential efficacy outcome: Hospital length of stay
Total hospital length of stay (hours) among admitted participants.
Measured: From hospital admission to hospital discharge, up to 120 hours
Safety outcome: Air Leak Syndrome
Proportion of participants with air leak complications (e.g., pneumothorax, pneumomediastinum, pneumopericardium, or subcutaneous emphysema).
Measured: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Vomiting
Proportion of participants experiencing vomiting.
Measured: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Pulmonary aspiration
Proportion of participants with suspected aspiration, defined as emesis followed by new findings on chest radiograph.
Measured: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Systolic hypotension
Proportion of participants with systolic blood pressure below the 5th percentile for age (defined as <70 mmHg + [2 × age in years]).
Measured: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Facial skin breakdown
Proportion of participants with facial pressure injury of Stage 2 or higher per National Pressure Injury Advisory Panel (NPIAP) criteria.
Measured: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start1 Dec 2026 (estimated)
- Primary completionJul 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric AsthmaStudies of the same condition, open and under way.
- More trials run by Columbia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Columbia University
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital of Philadelphia, Nationwide Children's Hospital, University of Utah, National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Maria Kwok, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07582211
- Sponsor's protocol ID
- ACYY1620
- Other IDs
- 1R34HL173384-01A1
- Status last verified
- Nov 2026
- First submitted
- 6 May 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bilevel Positive Airway Pressure (BPAP) for Severe Asthma Exacerbations: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07582211
- Acronym / sponsor ID
- ACYY1620
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Columbia UniversityUniversity, hospital or other
- Collaborators
- Children's Hospital of Philadelphia, Nationwide Children's Hospital, University of Utah, National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach.
The main questions it aims to answer are:
- Can eligible patients be successfully enrolled and complete study procedures across multiple sites?
- What safety events occur with early BPAP use in this population?
- How do clinical outcomes (such as symptom improvement and need for intensive care) compare between early BPAP and standard care?
Researchers will compare early initiation of BPAP plus standard asthma therapy to standard asthma therapy alone to determine whether early BPAP is a feasible and potentially beneficial treatment strategy.
Participants will 1) receive standard asthma therapy with or without early BPAP in the ED, 2) be monitored closely during the ED visit and hospitalization, and 3) have clinical data collected from routine care, including asthma severity scores, treatments, and outcomes.
The study will enroll approximately 36 participants (about 12 per site) across three sites over one year to inform a future multicenter randomized controlled trial.
Detailed description
Severe asthma exacerbations are a common reason for pediatric emergency department (ED) visits, hospital admissions, and pediatric intensive care unit (PICU) use. Although first-line therapies such as inhaled beta-agonists, anticholinergics, and systemic corticosteroids are well established, the optimal second-line treatment for children who remain in moderate to severe respiratory distress is unclear.
Bilevel positive airway pressure (BPAP) is a form of non-invasive positive pressure ventilation that may improve airway patency, reduce work of breathing, improve ventilation-perfusion matching, and enhance delivery of inhaled bronchodilator therapy. Prior pediatric studies suggest potential physiologic and clinical benefit, but available randomized trials have been small and have generally evaluated BPAP after PICU admission rather than early in the ED course. Therefore, the feasibility, safety, and potential clinical impact of early ED initiation of BPAP remain uncertain.
This multicenter, randomized, unblinded feasibility trial will enroll approximately 36 children across three sites. Participants will be children with severe asthma exacerbations who remain symptomatic after completion of standard first-line therapy and continue to require continuous albuterol. Patients will be randomized to receive either BPAP plus continuous albuterol or continuous albuterol alone during an approximately 2-hour intervention period. BPAP will be delivered using FDA-cleared devices, with mask interface and pressure settings managed according to routine clinical practice. After the intervention period, all further asthma treatment and respiratory support will be determined by the treating clinical team.
The primary purpose of this study is to assess feasibility of conducting a future definitive multicenter randomized trial. Feasibility domains include patient identification, consent and assent processes, timely randomization, BPAP initiation and adherence, completion of asthma severity assessments, and collection of clinical and safety data. Clinical outcomes, including asthma severity, duration of continuous albuterol, BPAP use, ED disposition, PICU and hospital admission, length of stay, and readmission, will be summarized descriptively. Safety monitoring will include adverse events potentially related to BPAP or continuous albuterol, including air leak syndrome, vomiting, aspiration, hypotension, skin breakdown, tachycardia, and tremor.
This feasibility trial is not powered to detect treatment efficacy. Results will be used to refine trial procedures, assess protocol adherence, estimate enrollment and data completion rates, and inform the design of a future multicenter randomized trial evaluating whether early ED initiation of BPAP reduces critical care resource use and improves outcomes in children with severe asthma exacerbations.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BPAP plus continuous albuterol | Experimental | Device: Bilevel positive airway pressure ventilationParticipants randomized to this arm will receive BPAP plus continuous albuterol administered via FDA-approved delivery systems according to routine clinical practice. BPAP will be delivered using an appropriately sized nasal or face mask and managed by trained respiratory therapists and/or nursing staff per standard care. Continuous albuterol will be administered through the BPAP circuit per manufacturer recommendations or site-specific practice. BPAP settings may be adjusted at the discretion of the treating clinician. Participants will remain on BPAP for approximately 2 hours or until continuous albuterol is discontinued, whichever occurs first. After the intervention period, continuation of BPAP will be at the treating clinical team's discretion. |
| Continuous albuterol alone | No intervention | –Participants randomized to this arm will receive continuous albuterol administered via FDA-approved delivery systems according to routine clinical practice. Non-invasive ventilation (including BPAP or CPAP) will not be initiated during the first approximately 2 hours after randomization unless clinically indicated; if initiated, the reason will be documented. All other aspects of care, including oxygen and adjunctive therapies, will be provided at the discretion of the treating clinical team per standard practice. After the intervention period, escalation of care, including initiation of BPAP or other respiratory support, will be determined by the treating clinician. |
Who may qualify
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- 5 to 17 years of age (inclusive) presenting to the ED with an asthma exacerbation.
- Demonstrate moderate-severe asthma exacerbation at triage (i.e., receive an institutional asthma score equivalent to moderate-severe asthma exacerbation or a Pediatric Respiratory Assessment Measure (PRAM) score of 6 or above).
Key exclusion criteria (23 listed)
- Prior participation in the study.
- Use of BPAP at any time within approximately 12 hours for this acute asthma exacerbation, including in prehospital, ED, or inpatient settings, prior to randomization.
- Receipt of continuous albuterol for over 150 minutes prior to being approached for consent.
- If a blood gas is obtained, PaCO2 greater than 60 mmHg on the most recent blood gas prior to being approached for consent.
- Note: Blood gas values are not required for eligibility confirmation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bilevel positive airway pressure ventilationThis study involves non-invasive positive pressure ventilation (NIPPV) delivered as bilevel positive airway pressure (BPAP) in children aged 5-17 years presenting to the pediatric emergency department with severe asthma exacerbations. BPAP will be administered using FDA-cleared devices according to their intended use and standard clinical practice. Therapy will be delivered via an appropriately fitted nasal or face mask and managed by trained clinical staff. Ventilator settings will be adjusted at the discretion of the treating clinician, and continuous bronchodilator therapy may be delivered through the BPAP circuit per manufacturer recommendations or site practice. | Device | BPAP plus continuous albuterol |
Primary outcome
Number of eligible patients who consent
Time frame: From screening through randomization, up to 2 hours
Proportion of approached, eligible patients who provide consent.
Proportion of participants who adhere to the BPAP protocol among all those assigned to the BPAP arm
Time frame: From randomization through end of 2-hour intervention
Proportion of participants in the intervention arm who receive > 1 hour \& 45 minutes of BPAP during the planned 2-hour intervention period without unplanned interruption (> 15 consecutive minutes), unless weaned off continuous albuterol.
12 secondary outcomes
Potential efficacy outcome: Change in Pediatric Respiratory Assessment Measure (PRAM) score
Time frame: Pre-intervention to end of intervention, approximately 3 hours total
Potential efficacy outcome: Duration of continuous albuterol use
Time frame: From randomization through hospital discharge beyond the intervention period, up to 120 hours.
Potential efficacy outcome: Duration of BPAP use
Time frame: From randomization through hospital discharge beyond the intervention period, up to 120 hours
Potential efficacy outcome: PICU admission
Time frame: Disposition determined 2 hours after completion of the intervention period
Potential efficacy outcome: Hospital admission
Time frame: Disposition determined 2 hours after completion of the intervention period
Potential efficacy outcome: PICU length of stay
Time frame: From PICU admission to PICU discharge, up to 120 hours
Potential efficacy outcome: Hospital length of stay
Time frame: From hospital admission to hospital discharge, up to 120 hours
Safety outcome: Air Leak Syndrome
Time frame: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Vomiting
Time frame: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Pulmonary aspiration
Time frame: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Systolic hypotension
Time frame: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Safety outcome: Facial skin breakdown
Time frame: From randomization until 4 hours post-randomization or until ED discharge, whichever occurs first.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Pediatric Asthma
Not yet recruiting
Asthma Ctrl SMART Trial
Asthma in Children, Asthma Chronic
Not yet recruiting
Artificially Intelligent Robot Control
Asthma in Children, Artificial Intelligence
Recruiting
Effects of Tele-rehabilitation-Guided Qigong on Children and Adolescents With Asthma
Asthma Childhood
Enrolling by invitationObservational study
Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.
Lung Diseases
Active, not recruitingPhase 3
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bilevel positive airway pressure ventilation in people with Pediatric Asthma and Acute Asthma, run by Columbia University at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maria Kwok, MD, MPH (917-375-2647, myk2102@cumc.columbia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of eligible patients who consent (time frame: From screening through randomization, up to 2 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.